Analyst Ratings January 28, 2026

Raymond James Lifts MSCI Price Target to $710 Citing Subscription Sales Strength

Analyst maintains Outperform as Q4 2025 results and recurring subscription momentum underpin bullish view despite near-term cash flow headwinds

By Priya Menon MSCI
Raymond James Lifts MSCI Price Target to $710 Citing Subscription Sales Strength
MSCI

Raymond James increased its price objective for MSCI Inc. to $710 from $690 while keeping an Outperform rating, pointing to robust net new recurring subscription sales in the company's Index and Private Assets segments. The firm sees this subscription momentum as a likely driver of improved subscription revenue growth, even as MSCI's 2026 cash flow outlook came in below expectations and the stock fell in pre-market trading after the quarterly report.

Key Points

  • Raymond James raised its MSCI price target to $710 from $690 and retained an Outperform rating.
  • The firm emphasized strong net new recurring subscription sales in MSCI's Index and Private Assets segments as likely to boost subscription revenue growth in coming quarters.
  • MSCI beat fourth-quarter 2025 expectations with EPS of $4.66 versus $4.58 expected and revenue of $822.5 million versus $820.45 million estimated; the stock fell in pre-market trading despite the beats.

Raymond James revised its price target for MSCI Inc. (NYSE:MSCI) upward to $710.00 from $690.00 and left its rating at Outperform, signaling continued confidence in the equity despite a mixed near-term cash flow outlook. The new target implies about a 17% upside from MSCI's then-current share price of $606.25, with the stock trading near a 52-week high of $634.99.

The brokerage firm highlighted MSCI's fourth-quarter 2025 financial results as the primary rationale for the move. Raymond James pointed to notable momentum in net new recurring subscription sales across MSCI's Index and Private Assets businesses, a development the firm said is likely to translate into stronger subscription revenue growth in upcoming quarters.

MSCI's reported fourth-quarter 2025 earnings and revenue modestly exceeded Wall Street expectations. The company posted earnings per share of $4.66, above the forecasted $4.58, and generated revenue of $822.5 million compared with consensus estimates of $820.45 million. Despite the beats on both earnings and revenue, MSCI's shares declined during pre-market trading following the release.

Raymond James acknowledged that MSCI's 2026 cash flow outlook was below its prior expectations but characterized the shortfall as stemming from temporary factors rather than structural problems. The firm continued to describe MSCI's risk/reward profile as attractive, citing the company's pricing power, proprietary datasets, and ongoing tailwinds from secular trends in passive investing - factors the analyst believes support a premium valuation.

The analyst view ties the company's near-term performance to subscription sales execution. Strong net new recurring subscription sales in core segments were presented as the key indicator for revenue trajectory, while the 2026 cash flow projection introduced a recognized uncertainty that Raymond James expects to be transitory.

In sum, the Raymond James note raises the firm's valuation stance on MSCI on the basis of subscription sales strength and persistent structural advantages, while flagging a below-expectations cash flow outlook for 2026 as a temporary headwind that has not altered the overall Outperform stance.

Risks

  • MSCI's 2026 cash flow outlook came in below expectations, introducing uncertainty about near-term cash generation - this affects investor sentiment and valuation.
  • The stock declined in pre-market trading after the quarterly report, indicating potential market sensitivity to forward guidance even when earnings and revenue beat estimates.
  • Future subscription revenue growth is tied to continued net new recurring subscription sales momentum; any slowdown in these sales could dampen revenue trajectory.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026